Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to $56.6 million.

  • Marimed's Total Current Liabilities rose 2687.85% to $56.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.6 million, marking a year-over-year increase of 2687.85%. This contributed to the annual value of $50.0 million for FY2024, which is 6203.42% up from last year.
  • Marimed's Total Current Liabilities amounted to $56.6 million in Q3 2025, which was up 2687.85% from $50.9 million recorded in Q2 2025.
  • Marimed's Total Current Liabilities' 5-year high stood at $56.6 million during Q3 2025, with a 5-year trough of $14.6 million in Q1 2021.
  • Moreover, its 5-year median value for Total Current Liabilities was $30.9 million (2023), whereas its average is $34.2 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 5800.87% in 2021, then soared by 13488.51% in 2022.
  • Marimed's Total Current Liabilities (Quarter) stood at $27.2 million in 2021, then fell by 2.69% to $26.5 million in 2022, then rose by 16.5% to $30.9 million in 2023, then skyrocketed by 62.03% to $50.0 million in 2024, then grew by 13.15% to $56.6 million in 2025.
  • Its Total Current Liabilities was $56.6 million in Q3 2025, compared to $50.9 million in Q2 2025 and $55.3 million in Q1 2025.